Cambridge Investment Research Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-9,542	Closed	-$231K	–	3042
2022 Q1	$231K	Hold	9,542	–	–	﹤0.01%	2757
2021 Q4	$223K	Sell	9,542 -2,314	-20%	-$46.5K	﹤0.01%	2781
2021 Q3	$197K	Sell	11,856 -200	-2%	-$3.85K	﹤0.01%	2822
2021 Q2	$294K	Sell	12,056 -294	-2%	-$6.64K	﹤0.01%	2487
2021 Q1	$319K	Buy	+12,350	New	+$544K	﹤0.01%	2233

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cambridge Investment Research Advisors's ACAD Position: Q2 2022 in Review

Cambridge Investment Research Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q2 2022, closing a stake of 9,542 shares — an estimated $231K sold.

Cambridge Investment Research Advisors first reported a position in ACAD in Q1 2021 and held it in 5 quarters. The position peaked at $319K in Q1 2021. 246 funds tracked by Wall St. Rank hold ACAD as of Q2 2022.

Cambridge Investment Research Advisors reported no remaining Acadia Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Cambridge Investment Research Advisors sold 9,542 Acadia Pharmaceuticals shares in Q2 2022, an estimated $231K.
Cambridge Investment Research Advisors first reported a position in Acadia Pharmaceuticals in Q1 2021 and held it in 5 quarters.
Cambridge Investment Research Advisors's Acadia Pharmaceuticals position peaked at $319K in Q1 2021.
246 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2022.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2022, filed 13 Jul 2022.